Maxim Group analyst Michael Okunewitch has maintained their neutral stance on GILD stock, giving a Hold rating on April 28.
Michael Okunewitch has given his Hold rating due to a combination of factors influencing Gilead Sciences’ current and future performance. The company’s first-quarter results for 2025 showed sales slightly below expectations, although earnings per share were marginally above consensus. Despite a strong cash position and reiterated guidance, Gilead faces challenges such as the Medicare Part D redesign, which is expected to impact growth in the near term.
While there are promising developments on the horizon, such as the potential expansion of the cell therapy portfolio and the anticipated FDA decision on Lenacapavir, these are not expected to contribute significantly to growth in the immediate future. The competition in oncology and the modest impact of new launches like Livdelzi also temper expectations. Consequently, Okunewitch maintains a Hold rating, reflecting the belief that Gilead’s shares are fairly valued at current levels, with limited potential for valuation expansion in the short term.
In another report released on April 28, HSBC also maintained a Hold rating on the stock with a $93.00 price target.